Co-Authors
This is a "connection" page, showing publications co-authored by ALEXANDER LAZAR and ANDREW FUTREAL.
Connection Strength
0.452
-
METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics. Nat Commun. 2024 Aug 25; 15(1):7312.
Score: 0.061
-
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
Score: 0.059
-
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023 Jun; 29(6):1550-1562.
Score: 0.056
-
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
Score: 0.055
-
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
Score: 0.053
-
Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021 01; 27(1):141-151.
Score: 0.048
-
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).
Score: 0.043
-
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.
Score: 0.040
-
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res. 2017; 7:11.
Score: 0.037